[Skip to Content]
[Skip to Content Landing]
Letters
August 1, 2001

Atorvastatin for Acute Coronary Syndromes—Reply

Author Affiliations
 

Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001

JAMA. 2001;286(5):532-535. doi:10.1001/jama.286.5.532

In Reply: In response to Dr Wierzbicki and colleagues, in the MIRACL study1 the significant reduction of the primary composite end point with atorvastatin was influenced most by a 26% reduction in recurrent unstable angina with objective evidence of ischemia requiring emergency rehospitalization, a finding with obvious clinical importance. However, it is important to note that the MIRACL study was not powered to detect significant differences in individual components of the primary composite end point. In fact, an 8% nonsignificant reduction in death and nonfatal myocardial infarction with atorvastatin also contributed to the significant reduction of the primary composite end point.

First Page Preview View Large
First page PDF preview
First page PDF preview
×